The Lausanne Institutional Biobank: a new resource to catalyse research in personalised medicine and pharmaceutical sciences.

Breakthrough technologies which now enable the sequencing of individual genomes will irreversibly modify the way diseases are diagnosed, predicted, prevented and treated. For these technologies to reach their full potential requires, upstream, access to high-quality biomedical data and samples from large number of properly informed and consenting individuals and, downstream, the possibility to transform the emerging knowledge into a clinical utility. The Lausanne Institutional Biobank was designed as an integrated, highly versatile infrastructure to harness the power of these emerging technologies and catalyse the discovery and development of innovative therapeutics and biomarkers, and advance the field of personalised medicine. Described here are its rationale, design and governance, as well as parallel initiatives which have been launched locally to address the societal, ethical and technological issues associated with this new bio-resource. Since January 2013, inpatients admitted at Lausanne CHUV University Hospital have been systematically invited to provide a general consent for the use of their biomedical data and samples for research, to complete a standardised questionnaire, to donate a 10-ml sample of blood for future DNA extraction and to be re-contacted for future clinical trials. Over the first 18 months of operation, 14,459 patients were contacted, and 11,051 accepted to participate in the study. This initial 18-month experience illustrates that a systematic hospital-based biobank is feasible; it shows a strong engagement in research from the patient population in this University Hospital setting, and the need for a broad, integrated approach for the future of medicine to reach its full potential.

[1]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[2]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[3]  P. Mitteroecker,et al.  Variation at Genes Influencing Facial Morphology Are Not Associated with Developmental Imprecision in Human Faces , 2014, PloS one.

[4]  Lazare Benaroyo,et al.  Enjeux éthiques et sociaux de la médecine génomique , 2014 .

[5]  Pierre Maillard.  Sequenzierung des menschlichen Genoms und die Gesellschaft , 2014 .

[6]  J. Hubaux,et al.  Patient privacy in the genomic era. , 2014, Praxis.

[7]  G. Ginsburg,et al.  Medical genomics: Gather and use genetic data in health care , 2014, Nature.

[8]  Kenneth Offit,et al.  Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention , 2014, Science.

[9]  L. Benaroyo,et al.  [Ethical and social issues associated with genomic medicine]. , 2014, Praxis.

[10]  P. Maillard.  [Sequencing the human genome and society]. , 2014, Praxis.

[11]  Alex P. Reiner,et al.  Loss-of-Function Mutations in APOC 3 , Triglycerides , and Coronary Disease , 2014 .

[12]  Melissa A. Basford,et al.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data , 2013, Nature Biotechnology.

[13]  Li Li,et al.  The benefits of using genetic information to design prevention trials. , 2013, American journal of human genetics.

[14]  V. Gebski,et al.  Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. , 2012, JAMA.

[15]  L. Hood,et al.  A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.

[16]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[17]  Claudio J. Verzilli,et al.  An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People , 2012, Science.

[18]  M. Gerstein,et al.  The Centers for Mendelian Genomics: A new large‐scale initiative to identify the genes underlying rare Mendelian conditions , 2012, American journal of medical genetics. Part A.

[19]  Armin Koch,et al.  Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.

[20]  P. Visscher,et al.  Five years of GWAS discovery. , 2012, American journal of human genetics.

[21]  W. Sadee.  Genomics and personalized medicine. , 2011, International journal of pharmaceutics.

[22]  Taylor J. Maxwell,et al.  Deep resequencing reveals excess rare recent variants consistent with explosive population growth , 2010, Nature communications.

[23]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[24]  David M. Evans,et al.  Genome-wide association analysis identifies 20 loci that influence adult height , 2008, Nature Genetics.

[25]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[26]  Vincent Mooser,et al.  The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome , 2008, BMC cardiovascular disorders.

[27]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[28]  Michelle Meadows,et al.  Genomics and personalized medicine. , 2005, FDA consumer.

[29]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[30]  H. Mabuchi,et al.  Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981. , 1981, Atherosclerosis. Supplements.

[31]  H. Mabuchi,et al.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. , 1981, The New England journal of medicine.